Massive biotech bet!
The pharmaceutical company has bought 99% stakes in five coal processing companies since 2011.
Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.
The FTC is concerned that the Walgreens and Rite Aid deal would result in higher drug prices for consumers.
The court ruled that state courts can't hear claims against an out-of-state company if the alleged injuries didn't occur there.
The drugstore chain, which alleged that the blood testing startup breached their contract, is set to get $30 million but terms could change.
AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.
The fluorescence imaging technology company has agreed to sell to Stryker for $11.75 per share.
Positive clinical trial results and newly priced-in competition breed some optimism for UBS Analyst Carter Gould.
Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.
New CEO, nice dividend and a modest price make the stock look good here.
Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.
Positive subscription trends and less downside risk this year have the company well positioned, Mizuho says.
Don't think you need long-term care insurance? Give Tracy Byrnes 60-seconds and she will explain why you do.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat